Author/Authors :
Ashby، نويسنده , , Dale T. and Aymong، نويسنده , , Eve A. and Tcheng، نويسنده , , James E. and Grines، نويسنده , , Cindy L. and Cox، نويسنده , , David A. and Mehran، نويسنده , , Roxana and Garcia، نويسنده , , Eulogio and Griffin، نويسنده , , John J. and Guagliumi، نويسنده , , Giulio and Stuckey، نويسنده , , Thomas and Turco، نويسنده , , Mark and Lansky، نويسنده , , Alexandra J. and Stone، نويسنده , , Gregg W، نويسنده ,
Abstract :
The utility of glycoprotein IIb/IIIa receptor inhibitors as a “bail-out” modality after unsuccessful primary percutaneous coronary intervention for acute myocardial infarction is unknown. In the CADILLAC trial, of 1,030 control patients, 62 patients (6.0%) crossed over and received abciximab for procedural complications or suboptimal angioplasty results. Compared with patients who received routine upfront abciximab, those treated with bail-out abciximab had markedly lower rates of Thrombolysis In Myocardial Infarction grade 3 flow and increased rates of hemorrhagic and ischemic complications at 30 days and 1 year.
